Adverse events reported through postmarketing surveillance outside of the United States included inflammatory reaction, inflammatory nodule, unsatisfactory result, loss/lack of correction, allergic reaction, anxiety, vascular occlusion, infection, dry skin, increase/decrease in sensation, and abscess
In a cardiovascular outcomes trial, cholelithiasis occurred in 0.4% of lixisenatide-treated patients versus 0.2% in placebo-treated patients and acute cholecystitis in 0.3% of lixisenatide-treated patients versus 0.2% in placebo-treated patients
Although no study focused exclusively on individuals with diabetes, some were specifically limited to those with diabetes and undergoing insulin therapy
Ahrn B, Hirsch IB, Pieber TR, Mathieu C, Gmez-Peralta F, Hansen TK, et al
The most common side effects are mild digestive ones nausea, constipation, or acid reflux especially in the first weeks as your dose adjusts